Is Sorafenib on the market?

Sorafenib (Sorafenib) is a diaryl urea and oral multikinase inhibitor that targets cell surface tyrosine kinase receptors and downstream intracellular kinases involved in tumor cell proliferation and tumor angiogenesis. Sorafenib was first approved by the U.S. Food and Drug Administration (FDA) and the European Commission in 2007 for the treatment of hepatocellular carcinoma, and is also used to treat renal cancer and differentiated thyroid cancer.

Kinases are involved in tumor cell signaling, proliferation, angiogenesis and apoptosis. Sorafenib inhibits multiple intracellular serine/threonine kinases in the Ras/mitogen-activated protein kinase (MAPK) signaling pathway. The intracellular Raf serine/threonine kinase subtypes inhibited by sorafenib include Raf-1 (or C-Raf), wild-type B-Raf and mutant B-Raf. Sorafenib inhibits cell surface tyrosine kinase receptors such as KIT, FMS-like tyrosine kinase 3 (FLT-3), RET, RET/PTC, vascular endothelial growth factor receptor-1 (VEGFR-1), VEGFR-2, VEGFR-3, and platelet-derived growth factor receptor-β (PDGFR-β).

SorafenibThe original drug has been launched in China and has entered the scope of medical insurance. Different regions have different reimbursement ratios, and the price after reimbursement may vary. SpecificationsThe price of 0.2g*60 tablets may be around RMB 1,200. The original drug of sorafenib has also been launched overseas, and there are also sorafenib generic drugs produced in other countries. The specifications produced by Bangladesh Pharmaceutical FactoryThe price of 0.2g*60 tablets is around 450 yuan (the price may fluctuate due to the exchange rate). The pharmaceutical ingredients of the original drug are basically the same as those of the generic drugs. For specific prices and drug details, please consult the medical consultant of Yaode.